MILLBROOK, N.Y., April 8, 2008 /PRNewswire/ -- Donald C. Fresne, Chairman and CEO, Egenix, Inc., announced the appointment of Daniel Petrylak, MD as Chairman of the company’s scientific advisory board. Dr. Petrylak is currently Associate Professor of Medicine at Columbia University Medical Center where he is Director of Genitourinary Oncology, Division of Medical Oncology. He is the co-author of numerous peer reviewed scientific papers and is a national leader in the treatment of cancers of prostate, kidney, and bladder. Dr. Petrylak stated, “I enthusiastically look forward to working with the Egenix team. I believe the company’s initiatives for development of targeted translation inhibitors will reach the clinic in a timely fashion and provide unique benefits for patients with cancer.”
About Egenix, Inc.
Based in Millbrook, New York, Egenix, Inc. is a privately held biotechnology company responding to the demand for more effective cancer therapies. Egenix is developing small molecule inhibitors of translation initiation, a new paradigm in target-specific, non-cytotoxic anti-cancer therapy, and the use of translation initiation-specific biomarkers to assess tumor sensitivity to anti-cancer therapy with this novel class of anti-cancer drugs.
CONTACT: Donald C. Fresne, Chief Executive Officer, Egenix, Inc.,
+1-845-677-5317 or Fax, +1-845-677-3482, donaldcfresne@egenixinc.com
Web site: http://www.egenixinc.com/
